Metabomed

Company Overview

Snapshot

Founded in October 2013 by Eyal Gottlieb and Simone Botti, Metabomed operates with 1–10 employees. The company has raised $30.5M across 4 funding rounds from 7 investors. In May 2024, Metabomed ceased operations.

Business overview

Metabomed is a drug-discovery company focused on cancer metabolism within the Health Tech & Life Sciences sector. The company utilizes a proprietary target-identification platform, leveraging computational biology and metabolomics to develop drugs. Its core technology aims to inhibit targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells, thereby creating selective anticancer drugs that target cancer cells without harming normal cells. Metabomed operates in the Pharmaceuticals industry, serving the oncology and biotechnology markets.

Strategic signal

Metabomed ceased operations in May 2024. This indicates a significant and definitive end to the company's drug discovery efforts in cancer metabolism, signaling to investors and innovation teams that the venture has concluded its activities.

Company Intelligence Q&A

What is Metabomed's operational status?

Metabomed ceased to operate in May 2024.

When was Metabomed founded and by whom?

Metabomed was founded in October 2013 by Eyal Gottlieb and Simone Botti.

What was a key leadership change at Metabomed?

In September 2020, Metabomed appointed Ali Fattaey, Ph.D. as Chief Executive Officer.

Which investors participated in Metabomed's December 2019 funding round?

In December 2019, Metabomed secured funding from Yonjin Ventures and Boehringer Ingelheim Venture Fund.